Growth of B95-8 cells and expression of Epstein-Barr virus lytic phase in serum-free medium
- PMID: 2824833
- PMCID: PMC256028
- DOI: 10.1128/JVI.61.12.4033-4037.1987
Growth of B95-8 cells and expression of Epstein-Barr virus lytic phase in serum-free medium
Abstract
Epstein-Barr virus (EBV)-transformed tamarin (Saguinus oedipus) cells (B95-8) were selected for growth in medium with reduced serum and then transferred to serum-free medium which consisted of RPMI 1640 supplemented with insulin, transferrin, and selenium. Serum-free cells in continuous passage for 1 year had a morphology, growth rate, and culture density which approached those of B95-8 cells grown with serum. The cells expressed virus-induced antigens, including the EBV-associated DNA polymerase. Cells exposed to EBV-inducing agents, n-butyric acid and phorbol 12-myristate-13-acetate, produced transforming virus with titers comparable to those of cultures grown with serum. These findings demonstrate that serum is neither required for the growth of B95-8 cells nor necessary for induction or full expression of the EBV lytic phase in these cells.
Similar articles
-
Maintenance of growth transformation with Epstein-Barr virus is mediated by secretion of autocrine growth factors in two serum-free B-cell lines.J Virol. 1988 Sep;62(9):3415-21. doi: 10.1128/JVI.62.9.3415-3421.1988. J Virol. 1988. PMID: 2841494 Free PMC article.
-
Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV.J Virol. 2018 Feb 26;92(6):e01794-17. doi: 10.1128/JVI.01794-17. Print 2018 Mar 15. J Virol. 2018. PMID: 29263273 Free PMC article.
-
Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.J Virol. 2002 Jun;76(11):5612-26. doi: 10.1128/jvi.76.11.5612-5626.2002. J Virol. 2002. PMID: 11991990 Free PMC article.
-
The transforming prototype of Epstein-Barr virus (B95-8) is also a lytic virus.Int J Cancer. 1989 Jul 15;44(1):95-100. doi: 10.1002/ijc.2910440118. Int J Cancer. 1989. PMID: 2545637
-
Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.Autoimmunity. 2008 May;41(4):298-328. doi: 10.1080/08916930802024772. Autoimmunity. 2008. PMID: 18432410 Review.
Cited by
-
Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication.J Virol. 2007 Sep;81(18):9967-75. doi: 10.1128/JVI.02244-06. Epub 2007 Jul 11. J Virol. 2007. PMID: 17626073 Free PMC article.
-
Generation of human neutralizing monoclonal antibodies against the 2009 pandemic H1N1 virus from peripheral blood memory B lymphocytes.Cell Mol Immunol. 2013 Sep;10(5):403-12. doi: 10.1038/cmi.2013.25. Epub 2013 Aug 5. Cell Mol Immunol. 2013. PMID: 23912783 Free PMC article.
-
An Effective Neutralizing Antibody Against Influenza Virus H1N1 from Human B Cells.Sci Rep. 2019 Mar 14;9(1):4546. doi: 10.1038/s41598-019-40937-4. Sci Rep. 2019. PMID: 30872685 Free PMC article.
-
COX-2 induces lytic reactivation of EBV through PGE2 by modulating the EP receptor signaling pathway.Virology. 2015 Oct;484:1-14. doi: 10.1016/j.virol.2015.05.006. Epub 2015 Jun 5. Virology. 2015. PMID: 26057147 Free PMC article.
-
Maintenance of growth transformation with Epstein-Barr virus is mediated by secretion of autocrine growth factors in two serum-free B-cell lines.J Virol. 1988 Sep;62(9):3415-21. doi: 10.1128/JVI.62.9.3415-3421.1988. J Virol. 1988. PMID: 2841494 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials